Are we there yet? The Use of AI in Target and Drug Discovery

Time: 1:30 pm
day: Day One


• Addressing the hype cycle, and current expectations related to deployment of AI/ ML in early drug discovery
• How knowledge-based classification of proteins, combined with exhaustive annotations of drug-target-disease associations can inform and contextualize the decision-making process with respect to target selection
• The importance of in-depth domain expertise with respect to the development, interpretation and deployment of AI/ML models (XGBoost, MetaPath and 17 different types of “big” data) in target discovery for Type 2 Diabetes, Alzheimer’s disease and Autophagy